Clinical trials: Neoplasms, Metastatic
Metastatic Soft-tissue Sarcoma
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
This is a Phase I, open-label, dose-escalation and dose-expansion study of NOX66 given rectally, in cohorts of patients with metastatic soft tissue sarcoma (STS) who have not been exposed to anthracycline therapy, using a fixed…
- Trial name
- NCT05100628
- Testing
- NOX66, Doxorubicin
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Noxopharm Limited
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer
This Phase Ib-IIa, multi-institutional, open-label, dose-escalation study is designed to evaluate the safety, tolerability, pharmacokinetics and feasibility of trastuzumab emtansine (T-DM1) administered by intravenous (IV)…
- Trial name
- NCT00951665
- Testing
- paclitaxel, pertuzumab [Perjeta], trastuzumab emtansine [Kadcyla]
- Where
- 5 sites in United States
- Volunteers
- 107 people
- Sponsor
- Genentech, Inc.
Metastatic Colorectal Cancer
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
This clinical trial will be performed in previously untreated patients with metastatic colorectal cancer. The study will evaluate the safety, tolerability and efficacy of the study drug, CT-011, in combination with FOLFOX…
- Trial name
- NCT00890305
- Testing
- CT-011, FOLFOX
- Where
- 31 sites in United States, Bulgaria and 4 more
- Volunteers
- 171 people
- Sponsor
- Medivation, Inc.
Head and Neck Carcinoma, Adenocarcinoma
A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
This is a non-randomized, phase II, open label study of anlotinib hydrochloride capsules in recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is to evaluate the efficacy of anlotinib.
- Conditions
- Head and Neck Carcinoma, Adenocarcinoma, Recurrent Disease, Distantly Metastatic Malignant Neoplasm
- Trial name
- NCT03591666
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Metastatic Colorectal Cancer
Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy
This is a single centre prospective biological translational research study involving the collection of tumour tissue, blood samples and clinical data from patients being treated with regorafenib for metastatic Colorectal Cancer…
- Trial name
- PROSPECT-R (NCT03010722)
- Testing
- Regorafenib
- Where
- United Kingdom
- Volunteers
- 49 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Non Small Cell Lung Cancer, Metastatic
Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
The primary objective of this study is to establish the objective response rate (complete response + partial response) following treatment with VELCADE in combination with cisplatin plus gemcitabine in patients with locally…
- Trial name
- NCT01633645
- Testing
- Bortezomib, Gemcitabine, Cisplatin
- Where
- 5 sites in Greece
- Volunteers
- 53 people
- Sponsor
- University Hospital of Crete
NSCLC
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
Aumolertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR mutations.
- Trial name
- NCT05493501
- Testing
- Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- EQRx International, Inc.
Fatigue, Locally Advanced or Metastatic Breast Cancer
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer
Primary objective: To assess the efficacy of reparixin compared to placebo in limiting CRF in adult patients with locally advanced or metastatic breast cancer undergoing single-agent taxane chemotherapy, using FACITFatigue scale.
- Trial name
- NCT05212701
- Testing
- Reparixin
- Where
- 20 sites in United States, Germany and 1 more
- Sponsor
- Dompé Farmaceutici S.p.A
Advanced Non-Small Cell Lung Cancer
A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
The irinotecan and cisplatin combination showed significant anti-tumor activity. In the first-line setting, the investigators showed that this regimen had significant anti-tumor activity in 47% of chemo-naïve NSCLC patients with…
- Trial name
- NCT00874328
- Testing
- Irinotecan, Cisplatin, TS-1 (S-1)
- Where
- South Korea
- Volunteers
- 74 people
- Sponsor
- National Cancer Center, Korea
Prostate Cancer
Docetaxel Followed by Provenge in Metastatic Prostate Cancer
This clinical study will evaluate the role of combination therapy of docetaxel followed by Provenge for patients with metastatic castration-resistant prostate cancer (CRPC, (prostate cancer that is resistant to medical or…
- Trial name
- NCT02793765
- Testing
- Docetaxel, Sipuleucel-T
- Where
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
Solid Tumor
Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients
The purpose of this study is to determine whether cytoreduction of bulky metastatic disease using ultra high dose SBRT in combination with immunotherapy is tolerable and feasible In patients who have exhausted SoC treatment…
- Trial name
- NCT06416436
- Testing
- Atezolizumab, Stereotactic Ablative Radiotherapy (SBRT)
- Where
- United States
- Sponsor
- University of Kansas Medical Center
Colorectal Cancer
IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer
The main purpose of this study is to assess the efficacy and safety of IBI310 in combination with sintilimab in patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) locally advance or…
- Trial name
- NCT04258111
- Testing
- IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody)
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
- Trial name
- NCT02743611
- Testing
- BPX-701, Rimiducid
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Bellicum Pharmaceuticals
Breast Cancer, Metastatic Breast Cancer
Generative AI Patient Education Module for Breast Oncology
This study evaluates the safety, accuracy, and impact of an artificial intelligence (AI) tool designed to support patient education in breast cancer care for breast oncology patients under selected physicians care within the…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Carcinoma of the Breast
- Trial name
- NCT07512271
- Testing
- Survey (Participant), OpenEvidence CareConnect, Survey (Provider)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Efficacy and Safety of Estracyt® in Metastatic Breast Cancer
This study evaluates efficacy, safety and quality of life in patients affected by metastatic breast cancer RH+/ HER2- and treated by estramustine phosphate.
- Trial name
- BEST (NCT02853071)
- Testing
- Estramustine, standard practice
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Cancer, Metastatic Cancer
Biopsies of Cancer Patients for Tumor Molecular Characterization
In this research study, we are looking at performing a repeat biopsy of patients' tumors, even though they have already been diagnosed with cancer.
- Trial name
- NCT01061944
- Where
- United States
- Volunteers
- 188 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Adenocarcinoma Advanced or Metastatic
Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.
In Brazil pancreatic adenocarcinoma represents 2% of tumors, and 4% mortality being an uncommon disease, however very aggressive.Only 20% of cases are indicated for curative surgery, of which only 20% are alive within 5 years.
- Trial name
- NCT01971034
- Testing
- Paclitaxel, Metformin
- Where
- Brazil
- Volunteers
- 41 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer
This phase II trial tests how well photoimmunotherapy (PIT) with ASP-1929 in combination with cemiplimab works in treating patients with stage IIIB-IV non-small cell lung cancer (NSCLC) that has not responded to previous…
- Conditions
- Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT06943664
- Testing
- Biospecimen Collection, Cemiplimab, Cetuximab Sarotalocan Sodium
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
This phase II trial studies how well radium-223 dichloride and paclitaxel work in treating patients with advanced breast cancer that has spread to the bones.
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone
- Trial name
- NCT04090398
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 30 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Lung Cancer; Metastatic Lung Cancer
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
This is a Phase II, open-label, 4-cohort study of the monoclonal antibody BGB-A317 in combination with standard platinum-based chemotherapy in participants with advanced NSCLC or SCLC.
- Trial name
- NCT03432598
- Testing
- Tislelizumab, Paclitaxel, Gemcitabine
- Where
- 7 sites in China
- Volunteers
- 54 people
- Sponsor
- BeiGene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.